GORE Flow Reversal System and GORE Embolic Filter Extension Study

NCT ID: NCT01343667

Last Updated: 2016-02-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1397 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-04-30

Study Completion Date

2014-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to provide an ongoing evaluation of clinical outcomes associated with the GORE Flow Reversal System and the GORE Embolic Filter when used for embolic protection during carotid artery stenting.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Physicians will have the opportunity to select which embolic protection device, the GORE Flow Reversal System or the GORE Embolic Filter, to use during the carotid artery stenting procedure.

This study is not designed to compare study endpoints between the two treatment arms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carotid Stenosis Constriction, Pathologic Carotid Artery Diseases Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Arterial Occlusive Diseases Vascular Diseases Cardiovascular Diseases Pathological Conditions, Anatomical

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GFRS EPD

Carotid artery stenting with Gore Flow Reversal System embolic protection device

Group Type OTHER

Gore Flow Reversal System

Intervention Type DEVICE

Embolic protection by the GORE Flow Reversal System during carotid artery angioplasty and stenting

GEF EPD

Carotid artery stenting with Gore Embolic Filter embolic protection device

Group Type OTHER

Gore Embolic Filter

Intervention Type DEVICE

Embolic protection by the GORE Embolic Filter during carotid artery angioplasty and stenting

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gore Flow Reversal System

Embolic protection by the GORE Flow Reversal System during carotid artery angioplasty and stenting

Intervention Type DEVICE

Gore Embolic Filter

Embolic protection by the GORE Embolic Filter during carotid artery angioplasty and stenting

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Neuro Protection System GORE Neuro Protection System Parodi NPS FRS PAES proximal protection embolic filter distal protection

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient, or patient's legal representative, is able and willing to provide informed consent.
* Patient must be at least 18 years of age or older.
* Patient will be selected and treated according to the GORE Flow Reversal System Instructions for Use (IFU) or the GORE Embolic Filter IFU.

Exclusion Criteria

* Patient is contraindicated for the embolic protection device arm they are selected by the investigator to receive: Either Per the GORE Flow Reversal System IFU if the GORE Flow Reversal System is selected OR Per the GORE Embolic Filter IFU if the GORE Embolic Filter is selected

If the patient is contraindicated for both arms (devices) they may not be enrolled.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

W.L.Gore & Associates

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

W.L. Gore and Associates, Inc

Flagstaff, Arizona, United States

Site Status

Hoag Memorial Hospital

Newport Beach, California, United States

Site Status

University of California San Francisco

San Francisco, California, United States

Site Status

First Coast Cardiovascular Institute

Jacksonville, Florida, United States

Site Status

Emory University

Atlanta, Georgia, United States

Site Status

Kaiser FOundation Hospitals

Honolulu, Hawaii, United States

Site Status

Heart Care Research Foundation

Mokena, Illinois, United States

Site Status

Rockford Cardiovascular Associates

Rockford, Illinois, United States

Site Status

Indiana University

Indianapolis, Indiana, United States

Site Status

Ochsner Clinic

New Orleans, Louisiana, United States

Site Status

Johns Hopkins Hospital

Baltimore, Maryland, United States

Site Status

Beth Israel Decaoness Medical Center

Boston, Massachusetts, United States

Site Status

Harper Hospital

Detroit, Michigan, United States

Site Status

St John's Medical Center

Detroit, Michigan, United States

Site Status

St Joseph Mercy Hospital

Pontiac, Michigan, United States

Site Status

Covenant Medical Center

Saginaw, Michigan, United States

Site Status

St Anthony's Medical Center

St Louis, Missouri, United States

Site Status

St Joesph's Medical Center

St Louis, Missouri, United States

Site Status

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, United States

Site Status

Cooper University Hospital

Camden, New Jersey, United States

Site Status

Mercy Hospital

Buffalo, New York, United States

Site Status

Mt Sinai Hospital

New York, New York, United States

Site Status

St Francis Hospital

Roslyn, New York, United States

Site Status

Wake Heart Research

Raleigh, North Carolina, United States

Site Status

Forsyth Memorial Hospital

Winston-Salem, North Carolina, United States

Site Status

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status

Riverside Methodist Hospital

Columbus, Ohio, United States

Site Status

Southwest General Health Center

Middleburg Heights, Ohio, United States

Site Status

Heritage Valley Health Network

Beaver, Pennsylvania, United States

Site Status

Spirit Physician Services / Capital Cardiovascular Assoc

Camp Hill, Pennsylvania, United States

Site Status

Drexel University

Philadelphia, Pennsylvania, United States

Site Status

York Hospital

York, Pennsylvania, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Rapid City Regional Hospital

Rapid City, South Dakota, United States

Site Status

N. Central Heart Hospital

Sioux Falls, South Dakota, United States

Site Status

St Luke's Episcopal

Houston, Texas, United States

Site Status

Appleton Medical Cetner

Appleton, Wisconsin, United States

Site Status

University of Wisconsin

Madison, Wisconsin, United States

Site Status

St Lukes Medical Center

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FRS 09-05

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Evaluation of the GORE® Ascending Stent Graft
NCT05800743 ENROLLING_BY_INVITATION NA